STAT+: Acadia drug meets endpoints for treating Rett syndrome, a rare neurological disease
An experimental drug being developed by Acadia Pharmaceuticals improved the symptoms of women and girls with Rett syndrome, a rare genetic disease that robs patients of the ability to interact socially and can cause seizures and other neurological problems, the company said Monday.
The data were made public in a press release and have not yet been peer-reviewed.
